Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Parkinson's disease and essential tremor are chronic movement disorders for which there is no cure. When medication is no longer effective, deep brain stimulation (DBS) is recommended. Standard DBS is a neuromodulation method that uses a simple monophasic pulse, delivered from an electrode to stimulate neurons in a target brain area. This monophasic pulse spreads out from the electrode creating a broad, electric field that stimulates a large neural population. This can often effectively reduce motor symptoms. However, many DBS patients experience side effects - caused by stimulation of non-target neurons - and suboptimal symptom control - caused by inadequate stimulation of the correct neural target. The ability to carefully manipulate the stimulating electric field to target specific neural subpopulations could solve these problems and improve patient outcomes. The use of complex pulse shapes, specifically biphasic pulses and asymmetric pre-pulses, can control the temporal properties of the stimulation field. Evidence suggests that temporal manipulations of the stimulation field can exploit biophysical differences in neurons to target specific subpopulations. Therefore, our aim is to evaluate the effectiveness of complex pulse shapes to reduce side effects and improve symptom control in DBS movement patients.
The study had three stages. In the first stage, a wide range of investigatory pulse shapes in a small number of patients. The effect of the pulses on the therapeutic window will be assessed.
Stage 2 will perform a short-term chronic evaluation in a larger number of patients of the complex pulse shape selected as most interesting from stage 1.
Stage 3 will then focus on long-term evaluation (upto 2 years). Outcomes: see stage 2.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard clinical pulse shape | Active Comparator | Standard clinical pulse shape as used in clinical practice (cathodic stimulation). |
|
| Complex pulse shape | Experimental | Complex pulse shape (i.e. biphasic pulse shape anode first, biphasic pulse shape cathode first, hyperpolarizing pre-pulse or depolarizing pre-pulse) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Boston Scientific: Study tool computer | Device | compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape |
|
| Measure | Description | Time Frame |
|---|---|---|
| Stage 1: Therapeutic window = Amplitude at which therapeutic benefit is obtained versus amplitude at which side-effects occur, both expressed in mA (milliamperes). | Amplitude at which therapeutic benefit is obtained versus amplitude at which side-effects occur, both expressed in mA (milliamperes). | Immediately after testing |
| Stage 2 ET (3 hours): tremor scores | FTM (Fahn-Tolosa-Marin) total score. Max 116 (higher score for more tremor). | Measured after 3 hours of stimulation |
| Stage 2 ET (3 hours): ataxia scores | ICARS (International cooperative ataxia rating scale): total score. Max 100 (higher score for more ataxia). | Measured after 3 hours of stimulation |
| Stage 2 ET (1 week): number of treatment-related adverse events as assessed by CTCAE v4.0 | Follow-up of (S)AE related to the study during that week | During 1 week of stimulation |
| Stage 2 PD (1 week): number of treatment-related adverse events as assessed by CTCAE v4.0 | Follow-up of (S)AE related to the study during that week | During 1 week of stimulation |
| Stage 3 ET (2 years): number of treatment-related adverse events as assessed by CTCAE v4.0 | Follow-up of (S)AE related to the study during those 2 years | During 2 years of stimulation |
| Measure | Description | Time Frame |
|---|---|---|
| Stage 1: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | Follow-up of (S)AE related to the study upto 1 week after the experiment | Upto one week after the study visit of stage 1 |
| Stage 2 ET (3 hours): Therapeutic window: Amplitude to elicit tremor arrest, amplitude to elicit ataxia, amplitude to elicit stim-induced side-effects |
Not provided
Inclusion Criteria for PD:
Inclusion Criteria for ET:
General Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Myles Mc Laughlin, Prof. Dr. | KU Leuven | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| KU Leuven | Leuven | 3000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| D020329 | Essential Tremor |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Randomized, crossover, double-blinded design
Not provided
Not provided
Double-blinded design
Amplitude to elicit tremor arrest, amplitude to elicit ataxia, amplitude to elicit stimulation-induced side-effects (all expressed in mA) |
| Immediately after testing |
| Stage 2 ET (3 hours): tremor subscores | FTM (Fahn-Tolosa-Marin) subscores: items 5, 6, 11, 12 and 13 (max 48, higher score for more tremor) | Measured at 1 hours, 2 hours and 3 hours after start of stimulation |
| Stage 2 ET (3 hours): ataxia subscores | ICARS (international cooperative ataxia rating scale): item 10 (max 8, higher score for more ataxia) | Measured at 1 hours, 2 hours and 3 hours after start of stimulation |
| Stage 2 ET (3 hours): speech assessment (least dysarthria) | Tests: sustained phonation /a/, diadochokinesis /tatata/, text reading and spontaneous speech Outcome: which of both pulses has less dysarthria per test (either cathodic pulse, either experimental pulse) | Measured at 1 hours, 2 hours and 3 hours after start of stimulation |
| Stage 2 ET (1 week): tremor scores and subscores | FTM (Fahn-Tolosa-Marin) tremor rating scale:
| Measured after 1 week of stimulation |
| Stage 2 ET (1 week): ataxia subscores and total score | ICARS (international cooperative ataxia rating scale):
| Measured after 1 week of stimulation |
| Stage 2 ET (1 week): tremor measured with Kinesia One wearable | Amount of postural tremor and kinetic tremor in both hands (max 4 per side, higher score for more tremor) | Measured after 1 week of stimulation |
| Stage 2 ET (1 week): tremor time measured with Kinesia 360 | Amount of tremor time measured with Kinesia 360 wearable (%, higher score for more tremor time) | Measured during 1 week of stimulation |
| Stage 2 ET (1 week): speech assessment (least dysarthria) | Tests: sustained phonation /a/, diadochokinesis /tatata/, text reading and spontaneous speech Outcome: which of both pulses has less dysarthria per test (either cathodic pulse, either experimental pulse) | Measured after 1 week of stimulation |
| Stage 2 ET (1 week): cognition | MoCA (Montreal Cognitive Assessment). Max 30, higher score for better cognition. | Measured after 1 week of stimulation |
| Stage 2 ET (1 week): quality-of-life | QUEST (Quality-of-life in essential tremor questionnaire). Max 100%, higher score for worse quality-of-life. | Measured after 1 week of stimulation |
| Stage 2 ET (1 week): quality-of-life | VAS (visual analogue scale) for:
| Measured once daily during 1 week of stimulation |
| Stage 2 PD (1 week): therapeutic window (amplitude at loss of rigidity and amplitude at stim-induced side-effects) | Amplitude at loss of rigidity and amplitude at stimulation-induced side-effects | Immediately after testing |
| Stage 2 PD (1 week): assessment motor symptoms in Parkinson's | MDS-UPDRS-III (Movement Disorders Society Unified Parkinson's Disease Rating Scale, part III). Max 132, higher score for more parkinsonian symptoms. | Measured after 1 week of stimulation |
| Stage 2 PD (1 week): assessment non-motor symptoms in Parkinson's | NMSS (non-motor symptoms scale). Max 30, higher scores for more symptoms. | Measured after 1 week of stimulation |
| Stage 2 PD (1 week): assessment of motor symptoms in Parkinson's with Kinesia One wearable | Wearable scores finger tapping and hand opening. Max 4 per item, higher scores for more symptoms. | Measured after 1 week of stimulation |
| Stage 2 PD (1 week): assessment motor symptoms in Parkinson's with Kinesia 360 wearable | Wearable score amount of time that patient was bradykinetic and dyskinetic. Expressed as %, higher scores for more symptoms | Measured after 1 week of stimulation |
| Stage 2 PD (1 week): assessment of speech (least dysarthria) | Tests: sustained phonation /a/, diadochokinesis /tatata/, text reading and spontaneous speech Outcome: which of both pulses has less dysarthria per test (either cathodic pulse, either experimental pulse) | Measured after 1 week of stimulation |
| Stage 2 PD (1 week): cognition | MoCA (Montreal Cognitive Assessment). Max 30, higher score for better cognition. | Measured after 1 week of stimulation |
| Stage 2 PD (1 week): quality-of-life | PDQ-39 (Parkinson's disease Questionnaire): 39-item questionnaire on quality-of-life. Expressed in %, higher score for more symptoms. | Measured after 1 week of stimulation |
| Stage 2 PD (1 week): quality-of-life | VAS (visual analogue scale) for:
| Measured once daily during 1 week of stimulation |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |